US drugmaker Eli Lilly is investing about $700 million to establish an institute for researching and developing genetic medicines at a new site in the Seaport area of...
Lilly has announced plans to spend more than $1.5 billion on new manufacturing facilities in the US and Ireland, as it beefs up its global network to meet rising demand...
Loxo Oncology at Lilly and Foghorn Therapeutics are collaborating to create novel oncology medicines based on the latter’s Gene Traffic Control platform. Under the terms...
US drugmaker Eli Lilly has announced changes to its executive leadership team as it creates two new business units in order to strengthen its focus on introducing...
US drugmaker Eli Lilly has acquired Protomer Technologies, strengthening its diabetes portfolio. The deal gives Lilly full control over the privately held US biotech...
The US Food and Drug administration (FDA) has granted an Emergency Use Authorization (EUA) for the bamlanivimab-etesevimab antibody cocktail made by Eli Lilly for...
Eli Lilly is to buy Prevail Therapeutics, a US biotech focused on developing adeno-associated viral vector 9 (AAV9) gene therapies to treat neurodegenerative diseases, in...
Eli Lilly is wading into gene therapy, inking a deal with Precision BioSciences to develop in vivo gene therapies for three gene targets. The first target will be...
